BACE1 inhibitors, anti‐Aβ antibodies, and other approaches (receptor for advanced glycation end products (RAGE), PPAR, 5‐hydroxytryptamine‐6 (5‐HT6)), most drugs tested in phase III clinical trials for AD failed. Here, BACE1 is linked to Alzheimer disease.